Table 3 Literature review on linac-based SRS on BSM
Study | Population | Metastases | Median prescription dose (range) | Local control | Survival (median) | Neurological death rate | Death by local progression rate | Toxicity |
|---|---|---|---|---|---|---|---|---|
Samblàs et al. [28] | 28 | 30 | Median 11.1 Gy (5–20) | n/a | 16.8 months | 42.8% | 3.5% | n/a |
Hatiboglu et al. [10] | 60 | 60 | Median 15 Gy (8–18) | 1-y: 35% | 4 months | 7% | 2% | Hemiparesis (6.6%) Nausea/vomiting (6.6%) Headache (5%) Cranial nerve deficit (3%) Hemorrage (3%) |
Kelly et al. [29] | 24 | 24 | Median 13 Gy (8–16) | 1-y: 78.6% | 5.3 months | 12.5% | 0% | Ataxia (4%) Acute confusion (4%) |
Valery et al. [21] | 30 | 43 | Median 13.4 Gy (8.2–15) | 1-y: 79% | 10 months | 42% (8 of 19 assessable cases) | n/a | Headache (13%) |
Lin et al. [11] | 45 | 48 | Median 14 Gy (10–17) | 1-y: 88% | 11.6 months | n/a | n/a | Overall: 4.7% |
Sugimoto et al. [30] | 24 | 25 | 24–40 Gy/7–13 fr | 96% | 9 months | n/a | 0% | Nausea (4%) |
Present study | 105 | 111 | 35.7 Gy10 (23.8–60) | 1-y: 90.4% | 11 months | 24.7% | 2.8% | Headache (2.8%) Pseudoprogression (1%) |